Background: Whitlockite (WH), a magnesium-enriched calcium phosphate mineral, is emerging as a promising biomaterial in bone tissue engineering due to its chemical similarity to natural bone and dual role in promoting osteogenesis and regulating bone resorption. Compared to conventional materials like hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP), WH offers higher solubility, superior ion release (notably Mg2+), and enhanced bioactivity.
Objective: This systematic review evaluates the in vivo efficacy of WH-based biomaterials in bone regeneration. Key outcomes include bone volume fraction (BV/TV), bone mineral density (BMD), osteogenic marker expression, and histological bone quality.
Methods: A comprehensive search of PubMed, Web of Science, Google Scholar, and Cochrane Central was conducted up to March 2025. Eligible studies assessed WH-based materials in animal bone defect models with quantifiable regenerative outcomes. Two reviewers independently performed data extraction and quality assessment using the SYRCLE Risk of Bias tool. Meta-analysis was not feasible due to significant heterogeneity across models, scaffold types, and endpoints.
Results: Seventeen animal studies (rats, mice, rabbits) met inclusion criteria. WH was used in forms such as nanoparticles, granules, and scaffolds with polymers like chitosan and gelatin. WH consistently outperformed HA and β-TCP with up to a 2-6 % increase in BV/TV, BMD, and histological bone formation. Upregulation of ALP, OCN, RUNX2, and COL1 was observed. Doped WH variants and composites enhanced osteoinductive and angiogenic responses. No adverse effects were reported.
Conclusion: WH demonstrates superior osteogenic and biocompatible properties over traditional calcium phosphates. Future standardized, long-term studies are needed to support clinical translation for orthopedic and dental bone regeneration.
Background: Adjunctive therapies play a crucial role in enhancing the efficacy of non-surgical periodontal therapy (NSPT) by addressing the multifactorial nature of periodontal disease. Injectable platelet-rich fibrin (i-PRF) and metronidazole-infused PRF gel have emerged as potential biomaterials that promote periodontal regeneration and antibacterial effects, respectively.
Objective: To evaluate and compare the clinical efficacy of i-PRF and metronidazole-infused PRF gel as adjuncts to NSPT in patients with periodontitis.
Method: ology: A randomized controlled trial was conducted on 20 periodontal sites in patients with Stage II-III periodontitis. Sites were divided into two groups (n = 10 each), receiving either i-PRF or metronidazole-infused PRF gel following NSPT. Clinical parameters, including Oral Hygiene Index (OHI), Gingival Index (GI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL), were assessed at baseline, 4 weeks, and 3 months. Statistical analyses included the Mann-Whitney U test for intergroup comparisons and the Friedman test for intragroup comparisons.
Results: Both groups showed significant improvement in PPD and CAL over the study period (p < 0.001). The metronidazole-infused PRF gel group demonstrated a more pronounced reduction in GI and BOP compared to the i-PRF group (p = 0.01 and p = 0.66, respectively). Improvements in OHI were observed in both groups but were not statistically significant.
Conclusion: The study highlights the potential of metronidazole-infused PRF gel as a superior adjunct to NSPT due to its enhanced antimicrobial effects and periodontal tissue healing properties. Personalized therapeutic strategies incorporating bioactive materials can optimize periodontal treatment outcomes.

